IT1234826B
(it)
*
|
1989-01-30 |
1992-05-29 |
Alfa Wassermann Spa |
Derivati eparinici e procedimento per la loro preparazione
|
IT1237518B
(it)
*
|
1989-11-24 |
1993-06-08 |
Renato Conti |
Eparine supersolfatate
|
USRE38743E1
(en)
|
1990-06-26 |
2005-06-14 |
Aventis Pharma S.A. |
Mixtures of particular LMW heparinic polysaccharides for the prophylaxis/treatment of acute thrombotic events
|
FR2663639B1
(fr)
*
|
1990-06-26 |
1994-03-18 |
Rhone Poulenc Sante |
Melanges de polysaccharides de bas poids moleculaires procede de preparation et utilisation.
|
FR2669932B1
(fr)
*
|
1990-12-03 |
1994-07-01 |
Sanofi Sa |
Nouvel heparosane-n,o-sulfate, son procede de preparation et les compositions pharmaceutiques qui le contiennent.
|
US5280016A
(en)
*
|
1991-03-29 |
1994-01-18 |
Glycomed Incorporated |
Non-anticoagulant heparin derivatives
|
NO921495L
(no)
*
|
1991-04-16 |
1992-10-19 |
Seikagaku Kogyo Co Ltd |
Oligosakkarid og fremgangsmaate for dets fremstilling
|
SE9101155D0
(sv)
*
|
1991-04-18 |
1991-04-18 |
Kabi Pharmacia Ab |
Novel heparin derivatives
|
CZ232593A3
(en)
*
|
1991-05-02 |
1994-07-13 |
Yeda Res & Dev |
Pharmaceutical preparation for preventing and/or therapy of pathological states
|
US6750207B1
(en)
*
|
1992-05-01 |
2004-06-15 |
Yeda Research And Development Co. Ltd. |
Compositions for the regulation of cytokine activity
|
US5861382A
(en)
*
|
1992-05-01 |
1999-01-19 |
Yeda Research And Development Co. Ltd. |
Methods for regulation of active TNF-α
|
FR2691066B1
(fr)
*
|
1992-05-15 |
1995-06-09 |
Sanofi Elf |
Utilisation de glycosaminoglycanes exogenes, de leurs analogues ainsi que de leurs fragments, fractions et derives, pour la preparation de medicaments destines au traitement de thrombopenies.
|
AU686581B2
(en)
*
|
1992-11-10 |
1998-02-12 |
Yeda Research And Development Co. Ltd. |
Compositions for the regulation of cytokine activity
|
US5696100A
(en)
*
|
1992-12-22 |
1997-12-09 |
Glycomed Incorporated |
Method for controlling O-desulfation of heparin and compositions produced thereby
|
US5650389A
(en)
*
|
1993-03-01 |
1997-07-22 |
University Of Alabama At Birmingham Research Foundation |
Methods for the inhibition of complement activation
|
FR2704226B1
(fr)
*
|
1993-04-22 |
1995-07-21 |
Sanofi Elf |
3-desoxy oligosaccharides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
|
IT1264709B1
(it)
*
|
1993-07-12 |
1996-10-04 |
Italfarmaco Spa |
Derivati eparinici ad attivita' antimetastatica
|
US6127347A
(en)
*
|
1994-01-12 |
2000-10-03 |
Univ Michigan |
Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
|
US5583121A
(en)
*
|
1994-01-12 |
1996-12-10 |
Michigan State University |
Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
|
EP0758247A4
(en)
*
|
1994-05-06 |
1997-08-20 |
Glycomed Inc |
O-DESULFATED HEPARIN DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF
|
US5639469A
(en)
*
|
1994-06-15 |
1997-06-17 |
Minnesota Mining And Manufacturing Company |
Transmucosal delivery system
|
GB2299998B
(en)
*
|
1995-03-31 |
1997-03-26 |
Hamilton Civic Hospitals Res |
Compositions for inhibiting thrombogenesis
|
US5763427A
(en)
*
|
1995-03-31 |
1998-06-09 |
Hamilton Civic Hospitals Research Development Inc. |
Compositions and methods for inhibiting thrombogenesis
|
US5744457A
(en)
*
|
1995-03-31 |
1998-04-28 |
Hamilton Civic Hospitals Research Development Inc. |
Compositions and methods for inhibiting thrombogenesis
|
US6001820A
(en)
*
|
1995-03-31 |
1999-12-14 |
Hamilton Civic Hospitals Research Development Inc. |
Compositions and methods for inhibiting thrombogenesis
|
CA2235223A1
(en)
|
1995-10-30 |
1997-05-09 |
Massachusetts Institute Of Technology |
Rationally designed polysaccharide lyases derived from heparinase i
|
US7045585B2
(en)
*
|
1995-11-30 |
2006-05-16 |
Hamilton Civic Hospital Research Development Inc. |
Methods of coating a device using anti-thrombin heparin
|
US6491965B1
(en)
|
1995-11-30 |
2002-12-10 |
Hamilton Civic Hospitals Research Development, Inc. |
Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
|
US6562781B1
(en)
*
|
1995-11-30 |
2003-05-13 |
Hamilton Civic Hospitals Research Development Inc. |
Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
|
US5767269A
(en)
*
|
1996-10-01 |
1998-06-16 |
Hamilton Civic Hospitals Research Development Inc. |
Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
|
FR2763848B1
(fr)
*
|
1997-05-28 |
2000-01-28 |
Rhone Poulenc Rorer Sa |
Utilisation des heparines de bas poids moleculaire pour la prevention et le traitement du trauma du systeme nerveux central
|
AU7753898A
(en)
*
|
1997-06-06 |
1998-12-21 |
Hamilton Civic Hospitals Research Development, Inc. |
Modified low molecular weight heparin that inhibits clot associated coagulation factors
|
JP3342007B2
(ja)
|
1997-11-20 |
2002-11-05 |
郁男 山科 |
低分子ヘパリン修飾体及び皮膚潰瘍治療剤
|
EP1059304B1
(en)
*
|
1998-02-26 |
2006-04-26 |
Seikagaku Corporation |
Novel polysaccharide derivatives, process for the production thereof and medicinal compositions containing the same as the active ingredient
|
US6028061A
(en)
*
|
1998-06-18 |
2000-02-22 |
Children's Medical Center Corp |
Angiogenesis inhibitors and use thereof
|
US7056504B1
(en)
|
1998-08-27 |
2006-06-06 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase I and II
|
CA2341412A1
(en)
*
|
1998-08-27 |
2000-03-09 |
Massachusetts Institute Of Technology |
Rationally designed heparinases derived from heparinase i and ii
|
JP4633223B2
(ja)
*
|
1999-03-31 |
2011-02-16 |
生化学工業株式会社 |
血管内皮細胞増殖因子依存性血管内皮細胞増殖の抑制剤
|
US6597996B1
(en)
*
|
1999-04-23 |
2003-07-22 |
Massachusetts Institute Of Technology |
Method for indentifying or characterizing properties of polymeric units
|
BR0012202A
(pt)
*
|
1999-06-30 |
2002-04-02 |
Hamilton Civic Hospitals Res |
Composições de heparina de peso molecular médio (mmwh), método de tratamento de uma condição trombótica, método de prevenção da formação de um trombo, método de inibição da formação de trombos, composição farmacêutica, método de tratamento de trombose venosa profunda, método de prevenção de embolia pulmonar, método de preparação e usos de uma composição de mmwh
|
IT1316986B1
(it)
*
|
2000-01-25 |
2003-05-26 |
Sigma Tau Ind Farmaceuti |
Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
|
US20080139503A1
(en)
*
|
2000-01-25 |
2008-06-12 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
|
US7781416B2
(en)
*
|
2000-01-25 |
2010-08-24 |
Sigma-Tau Research Switzerland S.A. |
Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
|
AU4351201A
(en)
*
|
2000-03-08 |
2001-09-17 |
Massachusetts Inst Technology |
Heparinase iii and uses thereof
|
JP4633233B2
(ja)
*
|
2000-06-29 |
2011-02-16 |
生化学工業株式会社 |
クラミジア感染症処置剤
|
AU2001291549A1
(en)
*
|
2000-09-08 |
2002-03-22 |
Hamilton Civic Hospitals Research Development Inc. |
Antithrombotic compositions
|
ES2324701T3
(es)
*
|
2000-09-12 |
2009-08-13 |
Massachusetts Institute Of Technology |
Metodos y productos relacionados con heparina de peso molecular bajo.
|
WO2002032406A2
(en)
*
|
2000-10-18 |
2002-04-25 |
Massachusetts Institute Of Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
PT2343077E
(pt)
*
|
2001-09-12 |
2013-08-29 |
Sigma Tau Res Switzerland Sa |
Derivados de glicosaminoglicanos totalmente n-dessulfatados como inibidores da heparanase, capazes de atividade antiangiogénica e desprovidos de efeito anticoagulante
|
US7285536B2
(en)
|
2001-12-05 |
2007-10-23 |
Yeda Research And Development Co., Ltd. |
Anti-cancer therapeutic compounds
|
AU2003225724A1
(en)
*
|
2002-03-11 |
2003-09-29 |
Momenta Pharmaceuticals, Inc. |
Analysis of sulfated polysaccharides
|
EP1551852A4
(en)
*
|
2002-04-25 |
2007-03-21 |
Momenta Pharmaceuticals Inc |
METHOD AND PRODUCTS FOR MUCOSAL DELIVERY
|
ITMI20031679A1
(it)
*
|
2003-08-29 |
2005-02-28 |
Opocrin Spa |
Processo per la produzione di eparine a basso peso
|
EP1582531A1
(en)
|
2004-03-24 |
2005-10-05 |
Aventis Pharma S.A. |
Process for oxidizing unfractionated heparins and detecting presence or absence of glycoserine in heparin and heparin products
|
WO2007019554A2
(en)
*
|
2005-08-08 |
2007-02-15 |
Momenta Pharmaceuticals, Inc. |
Polysaccharides for delivery of active agents
|
EP1792621B1
(en)
|
2005-11-30 |
2012-04-04 |
Istituto di Ricerche Chimiche e Biochimiche "G. Ronzoni" |
Orally administrable heparin derivatives
|
US9139876B1
(en)
|
2007-05-03 |
2015-09-22 |
Momenta Pharmacueticals, Inc. |
Method of analyzing a preparation of a low molecular weight heparin
|
WO2009007224A1
(en)
*
|
2007-07-10 |
2009-01-15 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Low molecular weight heparin derivatives having neuroprotective activity
|
EP2205642B1
(en)
*
|
2007-11-02 |
2016-01-27 |
Momenta Pharmaceuticals, Inc. |
Non-anticoagulant polysaccharide compositions
|
US8569262B2
(en)
|
2007-11-02 |
2013-10-29 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
US8592393B2
(en)
|
2007-11-02 |
2013-11-26 |
Momenta Pharmaceuticals, Inc. |
Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
|
AU2009250803A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Crystal Clear Partnership |
Separation of polysaccharides by charge density gradient
|
WO2009155108A1
(en)
|
2008-05-30 |
2009-12-23 |
Momenta Pharmaceuticals, Inc. |
Saccharide structures and methods of making and using such structures
|
ES2817779T3
(es)
*
|
2010-01-19 |
2021-04-08 |
Momenta Pharmaceuticals Inc |
Evaluación de preparaciones de heparina
|
EP2558506B1
(en)
|
2010-04-16 |
2019-06-26 |
Momenta Pharmaceuticals, Inc. |
Tissue targeting
|
CN103096870B
(zh)
|
2010-06-17 |
2017-04-19 |
动量制药公司 |
调节毛发生长的方法和组合物
|
US9068957B2
(en)
|
2011-02-21 |
2015-06-30 |
Momenta Pharmaceuticals, Inc. |
Evaluating heparin preparations
|
US9475888B2
(en)
*
|
2011-12-19 |
2016-10-25 |
Dilafor Ab |
Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
|
WO2013095215A1
(en)
|
2011-12-19 |
2013-06-27 |
Dilaforette Ab |
Low anticoagulant heparins
|
SG11201406119WA
(en)
*
|
2012-03-26 |
2014-11-27 |
Dilafor Ab |
Combination treatment comprising sulphated glycosaminoglycans for inducing labor
|
EP3003324A4
(en)
|
2013-05-28 |
2017-01-25 |
Momenta Pharmaceuticals, Inc. |
Pharmaceutical compositions
|
GB2515315A
(en)
*
|
2013-06-19 |
2014-12-24 |
Dilafor Ab |
New Processes
|
CN108424474B
(zh)
*
|
2017-02-15 |
2023-07-25 |
清华大学 |
去抗凝肝素衍生物及其用于炎症性肠病的治疗
|
EP3997238A1
(en)
|
2019-07-09 |
2022-05-18 |
Optimvia, LLC |
Methods for synthesizing anticoagulant polysaccharides
|
EP4182452A1
(en)
|
2020-07-14 |
2023-05-24 |
Optimvia, LLC |
Methods for synthesizing non-anticoagulant heparan sulfate
|